Citigroup’s Lakewood-Amedex Biotherapeutics LABT Stock Holding History
Bought
Maintained
Sold
Other funds holding LABT
Citigroup's LABT Position: Q3 2026 in Review
Citigroup opened a new position in Lakewood-Amedex Biotherapeutics (LABT) in Q3 2026: 10,734 shares worth $10.3K. The stake represents ﹤0.01% of the portfolio and ranks #5183 among its holdings.
7 funds tracked by Wall St. Rank hold LABT as of Q3 2026.
- Citigroup held 10,734 shares of Lakewood-Amedex Biotherapeutics worth $10.3K as of Q3 2026.
- Lakewood-Amedex Biotherapeutics was a new Citigroup position in Q3 2026.
- Lakewood-Amedex Biotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5183 holding.
- 7 funds tracked by Wall St. Rank held Lakewood-Amedex Biotherapeutics as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.